{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}],"title":"When DE Led to Ovarian Cancer Diagnosis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"226"}]}],"title":"When DE Did Not Lead to Ovarian Cancer Diagnosis"}],"denomUnitsSelected":"Positive Screens with Follow-up","denoms":[{"counts":[{"groupId":"OG000","value":"3531"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"5970"}],"units":"Positive Screens with Follow-up"}],"description":"Number of positive screens with complications","groups":[{"description":"Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years.","id":"OG000","title":"Ovarian Screening"}],"paramType":"NUMBER","populationDescription":"The units analyzed were positive screening exams with documented diagnostic follow-up. If a participant received 3 positive screens with documented follow-up after each one, she would be counted 3 times in the number of units analyzed.","reportingStatus":"POSTED","timeFrame":"One year from screening examination","title":"Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test","type":"SECONDARY","typeUnitsAnalyzed":"Positive Screens with Follow-up","unitOfMeasure":"Positive screens w/ complications"}